Filtros de búsqueda

Lista de obras de

A Case Report of Chronic Myelogenous Leukemia in a Patient With Multiple Myeloma and a Review of the Literature ⬇️

artículo científico publicado el 15 de noviembre de 2012

A case of IgD myeloma representing a missed biclonal paraproteinemia or isotype switch in a patient previously diagnosed with IgA–lambda myeloma ⬇️

artículo científico publicado el 13 de agosto de 2013

A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma

artículo científico publicado en 2020

A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma

artículo científico publicado en 2020

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

scientific article published on 16 December 2019

Complete Remission Achieved With Single Agent CNTO 328, an Anti–IL-6 Monoclonal Antibody, in Relapsed and Refractory Myeloma ⬇️

artículo científico publicado el 10 de enero de 2013

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

artículo científico publicado en 2016

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

scholarly article by Athanasios Dimopoulos et al published 20 September 2018 in Haematologica

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

scientific article published on 03 November 2020

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

artículo científico publicado en 2020

Erectile Dysfunction Associated With Bortezomib Treatment in a Patient With Multiple Myeloma and Amyloidosis ⬇️

artículo científico publicado el 17 de octubre de 2012

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

artículo científico publicado en 2020

Imipridone ONC201: combination therapy in hematologic malignancies

artículo científico publicado en 2018

Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review

scientific article published on 30 July 2020

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

artículo científico publicado en 2019

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

artículo científico publicado en 2017

Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd

scientific article published on 09 March 2020

Safety and Efficacy of Triplet Regimens in Newly Diagnosed Light Chain Amyloidosis ⬇️

artículo científico publicado el 24 de octubre de 2012

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study

artículo científico publicado en 2020

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

scientific article published on 03 July 2019

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda